NRX Pharmaceuticals, Inc. Accounts Receivable, before Allowance for Credit Loss
NRX Pharmaceuticals, Inc. (NRXP) had Accounts Receivable, before Allowance for Credit Loss of $412.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Assets › Accounts Receivable, after Allowance for Credit Loss
us-gaap:AccountsReceivableGross · last filed 2026-08-14
- 2026-06-30: Accounts Receivable, before Allowance for Credit Loss $412.00K.
- 2026-03-31: Accounts Receivable, before Allowance for Credit Loss $362.00K.
- 2025-12-31: Accounts Receivable, before Allowance for Credit Loss $314.00K.
- 2025-09-30: Accounts Receivable, before Allowance for Credit Loss $349.00K.
| Period end | Accounts Receivable, before Allowance for Credit Loss |
|---|---|
| 2026-06-30 | $412.00K 10-Q · filed 2026-08-14 |
| 2026-03-31 | $362.00K 10-Q · filed 2026-05-15 |
| 2025-12-31 | $314.00K 10-Q · filed 2026-08-14 |
| 2025-09-30 | $349.00K 10-Q · filed 2025-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |